cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Dr. dr. AAGP Wiraguna, SpKK(K), FINSDV, FAADV
Contact Email
-
Phone
+6282339990824
Journal Mail Official
editor.balidv@gmail.com
Editorial Address
Department of Dermatology and Venereology, Udayana University, Indonesia
Location
Kota denpasar,
Bali
INDONESIA
Bali Dermatology and Venereology Journal
Published by Universitas Udayana
ISSN : 26225417     EISSN : 2715694X     DOI : -
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Medicine & Pharmacology
Bali Journal of dermatology and venereology is published by Department of dermatology and venereology, Udayana University, Bali, Indonesia. Bali Journal of dermatology and venereology is an open access, peer reviewed journal aiming to communicate high quality research articles, reviews and general articles in the field of dermatology and venereology. Bali Journal of dermatology and venereology publishers articles which encompass all aspects of basic research/clinical studies related to the field of dermatology and venereology and allied science fileds. The Journal aims to bridge and integrate the intellectual, methodological, and substantive diversity of medical scholarship, and to encourage a vigorous dialogue between medical scholars and practitioners. The Journal welcomes contributions which promote the exchange of ideas and rational discourse between practicing educators and medical researchers all over the world.
Arjuna Subject : Kedokteran - Dematologi
Articles 5 Documents
 1 
Search results for , issue "Vol. 3 No. 2 (2020)" : 5 Documents clear
The effectiveness of galactomyces ferment filtrate, dexpanthenol and Centella asiatica combination serum in the treatment of post-acne hyperpigmentation We Sagara Dewi; Ivan Kurniadi; Anis Irawan Anwar
Bali Dermatology and Venereology Journal Vol. 3 No. 2 (2020)
Publisher : DiscoverSys Inc

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15562/bdv.v3i2.25

Abstract

Background: Acne vulgaris is a chronic inflammation of the pilosebaceous gland that may result in both non-inflammatory and inflammatory lesions. Post-acne hyperpigmentation (PAH) is caused by a hypermelanotic reaction to skin inflammation. It can occur secondary to the inflammation process and depending on the severity, may persist for a prolonged period.Objective To determine the effectiveness of galactomyces ferment filtrate (GFF), dexpanthenol, and Centella asiatica combination serum in the treatment of PAHMethods: This was a placebo-controlled randomized clinical trial. There are 68 subjects  that were divided into two groups: the experimental group received combination serum while the control group received placebo for 8 weeks. Three drops of serum were applied to the area with PAH twice daily in the morning and at night. The melanin, erythema, roughness, and L*, a*, and b* scores were assessed objectively using mexameter, chromameter and skin analyzer for every two weeks. Pearson’s correlation test and independent T-test were used to assess the trend of the parameters and compare the results of both groups.Results: The results of statistical calculations using Pearson correlation test showed the treatment group showed a significant decreasing trend of the melanin and spots score. Both groups showed significant decreasing trend in erythema, L* score and roughness. However, no significant difference was found between both groups in all parameters.Conclusion: The combination serum may decrease the melanin and spot scores suggesting that it affects the melanocyte activity. It has shown a good efficacy in treating PAH.
Dermatology in COVID-19 pandemic: a review of manifestation, prevention, and treatment of personal protective equipment adverse skin reactions I Gusti Ayu Nitya Indira; I Made Sutha Saskara
Bali Dermatology and Venereology Journal Vol. 3 No. 2 (2020)
Publisher : DiscoverSys Inc

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15562/bdv.v3i2.31

Abstract

Since declared as a global pandemic by World Health Organizations on 11th March 2020, per early July 2020, COVID-19 total confirmed cases count had surpassed 11 million cases. COVID-19 poses a new challenge to healthcare workers with a new standard of care and managing COVID-19 patients. Healthcare workers must adhere to stricter hand hygiene, and the new Personal Protective Equipment (PPE) protocol brings forth new problems for healthcare workers. Skin problems have become the most common and preventable adverse effects of the daily and prolonged use of PPE. This could inadvertently cause protocol breaches, such as mask touching, scratching, or off-protocol PPE adjustment. Damage in the skin could also cause discomfort, and skin exposure may serve as a new port of entry for a secondary infection. In this study, we review various studies regarding the adverse effects, prevention, and therapy of the skin problems related to COVID-19 PPE use.
Focus on the dabrafenib, vemurafenib, and trametinib in clinical outcome of melanoma: a systematic review and meta-analysis Ida Ayu Widya Anjani; Anak Agung Bagus Putra Indrakusuma; I Gede Krisna Arim Sadeva; Putri Ayu Wulandari; Luh Made Mas Rusyati; Prima Sanjiwani Saraswati Sudarsa; I Gede Putu Supadmanaba; Desak Made Wihandani
Bali Dermatology and Venereology Journal Vol. 3 No. 2 (2020)
Publisher : DiscoverSys Inc

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15562/bdv.v3i2.38

Abstract

Background: Melanoma is the most serious lethal skin cancer, affects the melanin producer cells (melanocytes). Surgery is the most common treatment, whereas for the advance stage the development of a treatment is recommended. BRAF (Dabrafenib and Vemurafenib) inhibitor or MEK inhibitor (Trametinib) is used as the most frequently targeted therapy of melanoma due to more than 80% patient with positive BRAF mutation. In this review, those treatments will be investigated systematically to identify their clinical outcome.Method: This systematic literature review (SLR) was performed from Cochrane, Science Direct, Google Scholar, and Pubmed. Cochrane Risk-of-Bias Tool RoB2 is used to assess RCT studies and New-castle Ottawa Scale Assessment to assess cohort studies by 3 different assessors. Data analysis was carried out by using Review Manager (RevMan 5.4). Heterogenicity test was assessed by I2  and Chi2 statisticResult: There are 20 studies used in this article (13 RCT and 7 cohorts). The overall survival (OS) and progression-free survival (PFS) of study that using targeted therapy (vemurafenib, trametinib, or dabrafenib) compare other therapies (chemotherapy, immunotherapy,etc) showed risk ratio (RR) was 1.12 (95%CI 1.07,1.17;  I2=100%; p<0,00001). The OS and PFS with monotherapy compare of vemurafenib, trametinib, or dabrafenib with combination therapy showed RR was 1.09 (95%CI.06,1.13;I2=99%; p<0,00001). Conclusion: BRAF and MEK targeted therapy has a good prognosis for a patient with a positive BRAF gene mutation and could be combined with other therapy for a better clinical outcome rather than monotherapy.Keyword: melanoma, dabrafenib, vemurafenib, and trametinib
Incidence and characteristic of psoriasis patients at Sanjiwani Gianyar Regional Hospital 2018-2019 Annisa Alviariza; Sayu Widyawati
Bali Dermatology and Venereology Journal Vol. 3 No. 2 (2020)
Publisher : DiscoverSys Inc

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15562/bdv.v3i2.39

Abstract

Introduction: psoriasis is a chronic inflammatory skin disease that is characterized by firmly demarcated red plaque covered by a thick squama as a result of impaired proliferation and differentiation of the epidermis. Diagnosis of psoriasis is based on history taking and clinical features. Treatment is determined based on the patient's clinical characteristics and the severity of the disease. Purpose: this retrospective study aims to determine the incidence, characteristics and treatment options of psoriasis patients in the dermatovenereology polyclinic of Sanjiwani Gianyar Regional Hospital in 2018-2019. Methods: retrospective study of psoriasis patients at Sanjiwani Gianyar Regional Hospital in 2018-2019. Data collected from medical records includes sociodemographic data, clinical data and patient treatment history. Results: Within two years, there were 53 new cases of psoriasis. The dominance of psoriasis cases were found in men with a ratio of women and men 1:2,31. From total 53 patients, 37 were male (69,81%)and 16 female patients (30,19%). The most common type was psoriasis vulgaris (73,58%). The most age group was 31-45 years. The most commonly given regimen of therapy was topical corticosteroids plus oral antihistamines (45,28%). The most widely given systemic therapy was methotrexate. Accompanying skin infections were found in 6 cases of psoriasis (11,32%). Conclusion: Based on the results of the study, there were 53 new cases of psoriasis in 2018-2019, psoriasis vulgaris was the most common, the most age group was 31-45 years old, topical corticosteroids plus antihistamines were still the main treatment options for psoriasis patients in Sanjiwani Gianyar Regional Hospital.
Systematic review of melasma treatments: advantages and disadvantages Sang Ayu Arta Suryantari; Ni Putu Tamara Bidari Sweta; Elvina Veronica; I Gusti Ngurah Bagus Rai Mulya Hartawan; Ni Luh Putu Ratih Vibriyanti Karna
Bali Dermatology and Venereology Journal Vol. 3 No. 2 (2020)
Publisher : DiscoverSys Inc

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15562/bdv.v3i2.41

Abstract

Background: Melasma is an acquired chronic hyperpigmentation mostly affecting women. The pathogenesis of melasma is uncertain but it predominant related to ultraviolet (UV) exposure. Due to chronic and relapsing nature, melasma is challenging to treat. The current available treatment often has undesirable side effects and suboptimal results. The principal of treatment includes protect from UV radiation, inhibit melanin synthesize and increase pathway to remove melanin. Objectives: To define available treatments for melasma and determine advantages and disadvantages including topical, oral and procedural. Method: Medline, Cochrane library and PubMed database were searched for articles from January 2011 to June 2020. Only RCTs, comparative, prospective, retrospective and systematic reviews focusing on melasma treatments were extracted, analyzed and discussed. Results: We found 197 studies that met the inclusion and exclusion criteria with 2314 participants included in this review. The treatments included topical, oral and procedural. In several studies, hydroquinone alone or combination remains the most effective treatment for melasma. Oral and topical tranexamic acid have been found to be a useful adjuvant treatment in refractory melasma with minimal adverse effects. Procedural treatment such as chemical peels, laser and light-based therapies, and microneedling have a mixed and unpredictable result. Overall, the side effects tend to be mild and affect few of the subject.Conclusions: The current state of the evidence suggests that some treatments with multiple modalities have their respective advantages and disadvantages. The choice of treatment modality must be adjusted according to the type of melasma such as its severity, extent and location. A better understanding of melasma through the further research may improve the therapy options with the least adverse effects.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2020 2020


Reset
Filter By Issues
All Issue Vol 4, No 2 (2021) Vol. 4 No. 2 (2021) Vol. 4 No. 1 (2021) Vol 4, No 1 (2021) Vol 3, No 2 (2020) Vol. 3 No. 2 (2020) Vol 3, No 1 (2020) Vol. 3 No. 1 (2020) Vol. 2 No. 2 (2019) Vol 2, No 2 (2019) Vol 2, No 1 (2019) Vol. 2 No. 1 (2019) Vol 1, No 2 (2018) Vol. 1 No. 2 (2018) Vol. 1 No. 1 (2018) Vol 1, No 1 (2018) More Issue